https://www.selleckchem.com/products/lxs-196.html
future longitudinal analyses. To assess the effects of treatment with lurasidone on risk for metabolic syndrome (MetS) in patients with schizophrenia. Rates of metabolic syndrome during treatment with lurasidone (40-160mg/d) were analyzed using pooled, short-term data from three randomized, double-blind, placebo-controlled studies (vs olanzapine and quetiapine XR); long-term data from two active-comparator-controlled studies (vs risperidone and quetiapine XR); and data from two open-label studies in which patients were switched from ola
Like
Comment
Share
